Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
Plain-language summary
This trial is testing an asparaginase-based regimen for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Sugemalimab (BIOLOGICAL): IV infusion | Placebo (DRUG): IV infusion | Pegaspargase (DRUG): Intramuscular injection | Gemcitabine (DRUG): IV infusion | Oxaliplatin (DRUG): IV infusion
Sugemalimab, Placebo, Pegaspargase, Gemcitabine, Oxaliplatin
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details